Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06652633 · ClinicalTrials.gov registry record · Phase 3
Long-term Follow-up of Participants Treated With Galapagos Chimeric Antigen Receptor (CAR) T-cell Therapies
A Phase 3 study, sponsored by Lakefront Biotherapeutics.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 546
- Enrollment target
NCT06652633: Recruiting Phase 3 study, sponsored by Lakefront Biotherapeutics.
NCT06652633 is a Phase 3 study that is actively recruiting participants, run by Lakefront Biotherapeutics. The registered enrollment target is 546 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (29% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06652633, a Phase 3 study, is actively recruiting participants, sponsored by Lakefront Biotherapeutics.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 546 participants
- Enrollment target
Study Summary
This is a long-term follow-up study for participants treated with Galapagos (GLPG) CAR T-cell therapies to evaluate the long-term safety and efficacy of GLPG CAR T-cell products for 15 years post infusion. Per Health Authorities guidelines for gene therapy medicinal products that utilize integrating vectors (e.g. lentiviral vectors), long term safety and efficacy follow up of treated patients is required. The purpose of this study is to monitor all participants exposed to GLPG CAR T-cell therapies for 15 years following their last CAR T-cell infusion to assess the risk of delayed adverse events (AEs) and the long-term benefit/risk profile and to monitor for replication-competent lentivirus (RCL) and CAR-T cell persistence.
Interventions
- GENETIC GLPG CAR T-cell therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 546 participants |
| Start Date | 2024-09-09 |
| Est. Completion | 2039-07 |
| Phase | Phase 3 |
What NCT06652633 shows while recruiting
NCT06652633 is an interventional study that assigns participants to a tested intervention. The registered 546 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (29% lower).
The record links to 0 conditions, and to 1 intervention - of which GLPG CAR T-cell therapy is the first listed.
NCT06652633 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06652633 about?
NCT06652633 is a clinical study titled "Long-term Follow-up of Participants Treated With Galapagos Chimeric Antigen Receptor (CAR) T-cell Therapies". This is a long-term follow-up study for participants treated with Galapagos (GLPG) CAR T-cell therapies to evaluate the long-term safety and efficacy of GLPG CAR T-cell products for 15 years post infusion. Per Health Authorities guidelines for gene therapy medicinal products that utilize integratin...
What is the current status of trial NCT06652633?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 546 participants. The study started on 2024-09-09. Estimated completion is 2039-07.
What interventions are being tested in trial NCT06652633?
The interventions under investigation include: GLPG CAR T-cell therapy (GENETIC).
Who is sponsoring clinical trial NCT06652633?
This trial is sponsored by Lakefront Biotherapeutics, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06652633's enrollment target sits among peer trials
546 689th of 2000 higher than 1,312 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03572374 · 546 participants · NA
Talking to Employers and Medical Staff About Breast Cancer Treatment and Your Job
- NCT05937685 · 546 participants · NA
Reducing Blood Pressure in Patients With High Cardiovascular Risk
- NCT06416150 · 546 participants · NA
Reducing Urban Cervical Cancer Disparities
- NCT06850922 · 546 participants · Phase 1
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7446603 Administered Alone or in Combination With Aflibercept or Faricimab in Participants With Diabetic Macular Edema
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI